AMSTERDAM, THE NETHERLANDS, December 13, 2022 – Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company has been awarded ‘Business Development Team of Year’ at the annual Scrip Awards ceremony held on the 30th of November, at […]
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to provide an update on a pivotal year of regulatory progress and commercial activities for MED3000. Read more…
Inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma Inobrodib is an oral drug showing good long-term tolerability at the recommended phase 2 dose as monotherapy Objective responses have been observed in heavily pre-treated relapsed/ refractory multiple myeloma patients Inobrodib is also being evaluated in combination with pomalidomide/ dexamethasone, with clear […]
12 December 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that, further to its announcement in July 2022, it has now received the initial results having completed the Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the […]
Congratulations to ISA Pharmaceuticals, Chief Scientific Officer & Founder, Professor Dr. Kees Melief who was recently awarded two prestigious awards at this year’s 37th Society for Immunotherapy of Cancer Annual Meeting for his outstanding contribution to the field of cancer immunotherapy and his longstanding commitment and achievements that have the potential to significantly improve patient […]
